济生肾气丸"异病同治"尿石症和骨质疏松症机制探讨OA
Discussion on the Mechanism of Jisheng Shenqi Pills in"Treatment Different Diseases with Same Method"of Urolithiasis and Osteoporosis
目的 运用网络药理学和分子对接方法,探讨济生肾气丸"异病同治"尿石症和骨质疏松症的作用机制.方法 通过TCMSP数据库筛选济生肾气丸的活性成分及作用靶点;利用OMIM、GeneCards、DrugBank数据库获取尿石症与骨质疏松症相关靶点,提取药物与疾病的共同靶点.采用STRING数据库构建共同靶点蛋白相互作用(PPI)网络,运用cytoHubba插件内置算法筛选核心靶点;利用R4.3.1 ClusterProfiler程序包进行GO功能与KEGG通路富集分析,明确主要生物学过程及信号通路;借助Cyto-scape软件构建活性成分-靶点-通路网络,通过网络拓扑分析确定关键活性成分;运用分子对接技术对结果进行验证.结果 共获得济生肾气丸活性成分116种,与尿石症和骨质疏松症相关的潜在靶点65个.核心靶点包括IL1B、MMP9、INS、IL6、TNF、PTGS2等.GO功能富集分析显示,主要生物学过程涉及活性氧代谢过程、活性氧代谢过程的调控、氧化应激反应等;KEGG通路富集分析提示,主要包括TNF、IL-17、PI3K-Akt等信号通路.分子对接结果显示,关键活性成分槲皮素、山柰酚与核心靶点具有良好结合能力.结论 济生肾气丸可能通过槲皮素、山柰酚、薯蓣皂苷元、汉黄芩素等活性成分作用于IL1B、MMP9、IL6、TNF等靶点,调控TNF、IL-17、PI3K-Akt等信号通路,进而调节炎症反应与氧化应激过程,实现对尿石症和骨质疏松症的"异病同治".
Objective To investigate the mechanism of Jisheng Shenqi Pills in treating urolithiasis and osteoporosis with the concept of"treatment different diseases with same method"using network pharmacology and molecular docking.Methods Active components and targets of Jisheng Shenqi Pills were screened from the TCMSP database,while disease targets for urolithiasis and osteoporosis were collected from OMIM;OMIM,GeneCards and DrugBank databases were used to obtain targets related to urolithiasis and osteoporosis,and then common targets of drugs and diseases were extracted.A protein-protein interaction(PPI)network of the intersection targets was constructed using the STRING database,and core targets were identified by the built-in algorithm of the cytoHubba plugin;GO and KEGG enrichment analyses were performed using the ClusterProfiler package in R 4.3.1 language to identify major biological processes and signaling pathways.A active ingredients targets-pathway network was constructed with Cytoscape software,and key active ingredients were screened based on network topology parameters;molecular docking was applied for validation.Results A total of 116 active ingredients of Jisheng Shenqi Pill were obtained,and 65 potential targets related to urolithiasis and osteoporosis were identified.Core targets included IL1B,MMP9,INS,IL6,TNF,PTGS2,etc.GO enrichment revealed that the main biological processes involved reactive oxygen species metabolic process,regulation of reactive oxygen species metabolic process and response to oxidative stress.KEGG enrichment indicated that major signaling pathways included the TNF,IL-17 and PI3K-Akt.Molecular docking demonstrated that the key active ingredients quercetin and kaempferol exhibited strong binding affinity with core targets.Conclusion The main active components of Jisheng Shenqi Pills,such as quercetin,kaempferol,diosgenin and wogonin,may active treating different diseases with same method of urolithiasis and osteoporosis through targets including IL1B,MMP 9,IL6 and TNF,by modulating signaling pathways such as TNF,IL-17 and PI3K-Akt,thereby regulating inflammatory responses and oxidative stress to realize the"same treatment for different diseases"of urolithiasis and osteoporosis.
许季;王永传;于龙潭;王进强;李冰雪;李鹏;高兆清;钟旭;刘铭
山东第二医科大学附属中医院(潍坊市中医院),山东 潍坊 261041山东第二医科大学附属中医院(潍坊市中医院),山东 潍坊 261041山东第二医科大学附属中医院(潍坊市中医院),山东 潍坊 261041山东第二医科大学附属中医院(潍坊市中医院),山东 潍坊 261041山东第二医科大学,山东 潍坊 261021山东第二医科大学附属中医院(潍坊市中医院),山东 潍坊 261041山东第二医科大学附属中医院(潍坊市中医院),山东 潍坊 261041山东第二医科大学附属中医院(潍坊市中医院),山东 潍坊 261041山东第二医科大学附属中医院(潍坊市中医院),山东 潍坊 261041
医药卫生
济生肾气丸尿石症骨质疏松症网络药理学异病同治
Jisheng Shenqi Pillsurolithiasisosteoporosisnetwork pharmacologytreatment different diseases with same method
《中国中医药图书情报杂志》 2026 (5)
10-15,6
国家中医药管理局科技司-山东省卫生健康委共建项目(GZY-KJS-SD-2023-025)山东省中医药科技项目(Q-2023034、ZR20240719)潍坊市科技发展计划项目(2025YX026)
评论